Immatics N.V.
Close on Oct 19, 2026
About Immatics
Biological Products, (No Diagnostic Substances), SIC 2836
Immatics is a biotechnology enterprise focused on research and development programs involving T-cell receptor therapies and proprietary database operations. The company develops early-stage and advanced TCER therapeutic programs alongside partner organizations. Its collaborators and commercial partners include major biopharmaceutical corporations such as Bristol Myers Squibb, Moderna, and Genmab, which participate through strategic license, development, and collaboration agreements.
The organization operates internationally with corporate entities and facilities located in Germany and the United States, alongside collaborative ventures connected to Denmark. Operating units include parent entity Immatics N.V., Immatics Biotechnologies GmbH in Germany, and Immatics US Inc. in the United States. The business utilizes laboratory equipment and office facilities across its operating regions, though a specific headquarters location is not explicitly designated in the provided text.
Summary of the business section of Immatics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Immatics N.V.
- Headquarters
- Tubingen, 2M
- Address
- Paul Ehrlich-Strasse 15 72076
- Phone
- 49 7071 5397 700
- Employees
- 304, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- P7
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers GmbHWirtschaftsprufungsgesellschaft, Stuttgart, Germany
Stock & identifiers
- Ticker
- IMTX
- Exchange
- Nasdaq
- Shares outstanding
- 134M, Dec 31, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 1809196
- CUSIP
- N44445109
- ISIN
- USN444451090
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jasuja Harpreet Singh | Chief Executive Officer, Director | 217,241 |
| James Nelson Pepin | Gen Counsel and Corp Secretary | – |
| Jordan Zeik Silverstein | Head of Strategy | 7,826 |
| Cedrik Michael Britten | Chief Medical Officer | 250 |
| Amie Elizabeth Krause | Chief People Officer | – |
| Carsten Alexander Johannes Reinhardt | Chief Development Officer | 47,781 |
| Steffen Martin Walter | Chief Operating Officer | 10,000 |
| Venkat Ramanan | Chief Financial Officer | – |
| Rainer Kramer | Chief Business Officer | – |
| Toni Michael Weinschenk | Chief Innovation Officer | – |
| Edward A. Sturchio Jr | General Counsel | – |
| Advisors Llc Perceptive | Director | – |
| Joseph Edelman | Director | 11,246,516 |
| Life Sciences Master Fund Ltd Perceptive | Director | – |
| Alise Reicin | Director | – |
| Eliot Forster | Director | – |
| Michael G. Atieh | Director | – |
| Heather L. Mason | Director | – |
| Paul Rutherford Carter | Director | – |
| Peter Alan Chambre | Director | 105,987 |
| Mathias Hothum | Director | 329,521 |
| Adam Leo Stone | Director | – |
Employees
Headcount reported in annual reports
“As of December 31, 2025, Immatics US employed 304 full-time employees, of which 45 hold doctorate degrees, 4 hold a law degree, and 4 hold medical degrees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 1, 2025 | Delisting | Notice of delisting from exchange (Form 25) |
| Jul 8, 2020 | Name change | Name changed from Immatics B.V. to Immatics N.V. |
| Jul 1, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |
| Apr 16, 2020 | Merger | Registration of securities for a merger or exchange offer (S-4) |